Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Headlines > Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

Published by Global Banking and Finance Review

Posted on September 15, 2025

1 min read

Last updated: January 21, 2026

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics - Headlines news and analysis from Global Banking & Finance Review

Tags:partnership investment

Quick Summary

Novartis has entered a $5.7 billion licensing deal with Monte Rosa Therapeutics to develop immune-mediated disease drugs, boosting Monte Rosa's shares by 50%.

Novartis Enters $5.7 Billion Licensing Agreement with Monte Rosa

Overview of the Licensing Deal

(Reuters) - Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases.

Details of the Agreement

Under the agreement, Monte Rosa Therapeutics will receive an upfront payment of $120 million and could earn up to $5.7 billion in total, including milestone payments and royalties on future drug sales.

Market Reaction

This marks Novartis’ second major deal this month, following an up-to-$5.2 billion deal with China's Argo Biopharmaceutical for experimental heart drugs.

Shares of Monte Rosa surged 50% in premarket trading after the announcement.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid)

Key Takeaways

•Novartis signs a $5.7 billion deal with Monte Rosa.
•Monte Rosa receives $120 million upfront.
•Potential earnings include milestone payments and royalties.
•This is Novartis' second major deal this month.
•Monte Rosa shares surged 50% post-announcement.

Frequently Asked Questions about Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

1What is the value of the licensing deal between Novartis and Monte Rosa?

The licensing deal is worth up to $5.7 billion, which includes milestone payments and royalties on future drug sales.

2How much upfront payment will Monte Rosa receive?

Monte Rosa Therapeutics will receive an upfront payment of $120 million as part of the agreement.

3What was the market reaction to the announcement?

Shares of Monte Rosa surged 50% in premarket trading following the announcement of the deal.

4What was Novartis' previous deal before this licensing agreement?

Before this deal, Novartis signed an up-to-$5.2 billion agreement with China's Argo Biopharmaceutical for experimental heart drugs.

5What types of diseases will the drugs developed under this deal target?

The drugs developed under this licensing deal will target immune-mediated diseases.

Overview of the Licensing Deal

(Reuters) - Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases.

Details of the Agreement

Market Reaction

This marks Novartis’ second major deal this month, following an up-to-$5.2 billion deal with China's Argo Biopharmaceutical for experimental heart drugs.

Shares of Monte Rosa surged 50% in premarket trading after the announcement.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid)

Frequently Asked Questions

1What is the value of the licensing deal between Novartis and Monte Rosa?

The licensing deal is worth up to $5.7 billion, which includes milestone payments and royalties on future drug sales.

2How much upfront payment will Monte Rosa receive?

Monte Rosa Therapeutics will receive an upfront payment of $120 million as part of the agreement.

3What was the market reaction to the announcement?

Shares of Monte Rosa surged 50% in premarket trading following the announcement of the deal.

4What was Novartis' previous deal before this licensing agreement?

Before this deal, Novartis signed an up-to-$5.2 billion agreement with China's Argo Biopharmaceutical for experimental heart drugs.

5What types of diseases will the drugs developed under this deal target?

The drugs developed under this licensing deal will target immune-mediated diseases.